Digest Network Come funziona
Network
/
Società
AI
Non verificato

AIRNA

Di cosa scriviamo

BiotecnologiaFarmaceuticaMercato del lavoroSaluteScienza

9 comunicati stampa

Guarda tutti i comunicati
28/04/2026
Eventi
Industria
Scienza
Biotecnologia
Farmaceutica
Sanità
Salute
Medicina - Varie
AIRNA to Present New Preclinical Data on RNA-Editing Therapeutic Pipeline at ASGCT Annual Meeting
Fonte
AIRNA
Emittente
Business Wire
1.00
0
07/04/2026
Industria
Scienza
Biotecnologia
Farmaceutica
Salute
Igiene alimentare
Medicina - Varie
AIRNA Announces First Patient Dosed in Phase 1 Trial of AIR-001, Potential Best-in-Class RNA-Editing Therapy for Alpha-1 Antitrypsin Deficiency (AATD)
Fonte
AIRNA
Emittente
Business Wire
1.00
0
01/10/2025
Biotecnologia
Salute
Scienza
Mercato del lavoro
AIRNA Appoints Allison Dorval as Chief Financial Officer and Niru Subramanian as Chief Operating Officer
Fonte
AIRNA
Emittente
Business Wire
1.00
0
06/08/2025
Biotecnologia
Salute
Scienza
Mercato del lavoro
AIRNA Appoints Tamara Joseph as Chief Legal Officer and Kristina Storey as Head of Regulatory Affairs
Fonte
AIRNA
Emittente
Business Wire
1.00
0
13/05/2025
Eventi
Biotecnologia
Farmaceutica
Salute
AIRNA Presents Data Supporting RNA Editing Approach for Alpha-1 Antitrypsin Deficiency (AATD) at 28th ASGCT Annual Meeting
Fonte
AIRNA
Emittente
Business Wire
1.00
0
16/04/2025
Mercato del lavoro
Industria
Scienza
Biotecnologia
Farmaceutica
Sanità
Salute
AIRNA Appoints Jacob Elkins Chief Medical Officer
Fonte
AIRNA
Emittente
Business Wire
1.00
0
01/04/2025
Scienza
Biotecnologia
Medicina - Varie
Sanità
Salute
Farmaceutica
AIRNA Raises Oversubscribed $155 Million Series B Financing to Fund Phase 1/2 Clinical Trial for Alpha-1 Antitrypsin Deficiency and Future Pipeline
Fonte
AIRNA
Emittente
Business Wire
1.00
0
30/01/2025
Biotecnologia
Farmaceutica
Salute
Mercato del lavoro
AIRNA Appoints Matthew Hawryluk as Chief Business Officer
Fonte
AIRNA
Emittente
Business Wire
1.00
0
31/07/2024
Salute
Biotecnologia
Medicina - Varie
Scienza
Mercato del lavoro
AIRNA Raises Oversubscribed $60 Million Financing to Advance New Class of RNA Editing Medicines and Progress Best-in-Class AATD Program into the Clinic
Fonte
AIRNA
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0